About Avillion
Avillion is a company based in London (United Kingdom) founded in 2012. The company has 2 employees as of December 31, 2017. Avillion offers products and services including Clinical Trial Management, Regulatory Expertise, and Quality Assurance. Avillion operates in a competitive market with competitors including Emmes, Syneos Health, Veristat, ClinChoice and Medelis WCCT Global, among others.
- Headquarter London, United Kingdom
- Employees 2 as on 31 Dec, 2017
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Avillion Llp
- Date of Incorporation 05 Oct, 2012
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Blackstone
& 2 more
-
Employee Count
2
as on Dec 31, 2017
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Avillion
Avillion offers a comprehensive portfolio of products and services, including Clinical Trial Management, Regulatory Expertise, and Quality Assurance.
End-to-end management of global clinical trials for drug development.
Strategic guidance for regulatory submissions across various markets.
Ensuring high standards in drug development processes and monitoring.
Funding Insights of Avillion
Investors in Avillion
Avillion has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Blackstone, Royalty Pharma and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in marketed and late-stage biopharmaceutical companies.
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Diversified investment management is provided across multiple asset classes.
|
Locked | Locked | Locked |
Investor details for Avillion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avillion
Investment portfolio details for Avillion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Avillion
Detailed financials for Avillion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Avillion Comparisons
Peer comparison for Avillion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Avillion
Avillion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Emmes, Syneos Health, Veristat, ClinChoice and Medelis WCCT Global, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Outsourced contract research organization services are provided to clients.
|
|
| Locked | Locked | Locked |
CRO clinical development services are provided by Syneos Health.
|
|
| Locked | Locked | Locked |
Clinical trials and regulatory submissions are supported as a CRO.
|
|
| Locked | Locked | Locked |
CRO focused on data management, regulatory affairs and consulting services
|
|
| Locked | Locked | Locked |
Full-service CRO expertise in influenza and oncology research is offered.
|
|
| Locked | Locked | Locked |
Full-service clinical research organization services are provided globally by Parexel.
|
Detailed competitors of Avillion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Avillion
Complete news archive for Avillion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avillion
Avillion was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Avillion is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Allison Jeynes-Ellis is the current CEO of Avillion.
As of Dec 31, 2017, the latest employee count at Avillion is 2.
Avillion, provides clinical co-development services.The company partners with pharmaceutical and biotechnology companies to co-develop and finance late-stage therapeutics. The companys services enable its partners to develop drugs without increasing the burden on their (partners) PL or cash reserves. As per the licencing agreement, the partners maintain absolute ownership of and control on commercialising the asset, while Avillion incurs 100 of the clinical and regulatory risk during the development of late-stage assets. The company receives milestone payments post-commercialisation of the successfully developed products. Avillion is backed by Abingworth, Clarus Ventures and Royalty Pharma. In December 2016, Avillion and Pfizer announced positive results from the Phase 3 BFORE trial demonstrating the superiority of BOSULIF (bosutinib) over Imatinib as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph) chronic myeloid leukaemia (CML).
Avillion's top competitors include Emmes, Syneos Health and ClinChoice.
Avillion offers Clinical Trial Management, Regulatory Expertise, and Quality Assurance.
Avillion has 3 investors. Key investors include Blackstone, Royalty Pharma, and Abingworth.